Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports
Authors:
Open Access
- 5 November 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-8
Abstract
Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization’s List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, both drugs are currently used off-label in hospitals worldwide and in numerous clinical trials for the treatment of SARS-CoV-2 infection. However, CQ and HCQ use has been associated with cardiac side effects, which is of concern due to the higher risk of COVID-19 complications in patients with heart related disorders, and increased mortality associated with COVID-19 cardiac complications. In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ. Additionally, we identified several confounding factors, including male sex, NSAID coadministration, advanced age, and prior diagnoses contributing to drug related cardiotoxicity. These findings may help guide therapeutic decision making and ethical trial design for COVID-19 treatment.Keywords
All Related Versions
This publication has 46 references indexed in Scilit:
- The Role of Aspirin in the Prevention of Cardiovascular DiseaseClinical Medicine & Research, 2014
- Rheumatoid arthritis and cardiovascular diseaseAmerican Heart Journal, 2013
- Cardiovascular disease in lupusCurrent Opinion in Rheumatology, 2013
- Heart Disease and Stroke Statistics—2011 UpdateCirculation, 2011
- A brief guide to model selection, multimodel inference and model averaging in behavioural ecology using Akaike’s information criterionBehavioral Ecology and Sociobiology, 2010
- Explaining odds ratios.2010
- Genetics of early-onset obsessive–compulsive disorderEuropean Child & Adolescent Psychiatry, 2010
- MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramJournal of the Medical Library Association, 2007
- Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemiaAnnals of the Rheumatic Diseases, 2005
- Rationale for interleukin-6 blockade in systemic lupus erythematosusLupus, 2004